Aptevo Therapeutics (APVO) vs HCW Biologics (HCWB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
HCW Biologics is the larger company by market cap ($3.6 million vs $3.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | APVO | HCWB |
|---|---|---|
| Share price | $1.79 | $1.60 |
| Market cap | $3.24M | $3.58M |
| 1-day change | -0.56% | +4.58% |
| P/E ratio (TTM) | 0.03 | — |
| EPS (TTM) | $66.59 | $-19.84 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $30.06 | $27.30 |
| 52-week low | $1.37 | $1.50 |
| Distance from 52-week high | -94.05% | -94.14% |
| Analyst consensus | none | buy |
| Avg. price target upside | +1324.58% | +2900.00% |
| Average volume | 90.91K | 377.00K |
| Shares outstanding | 1.81M | 2.24M |
| Employees | 33 | 35 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Aptevo Therapeutics
APVO stock →Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.
Health Care · Biotechnology: Pharmaceutical Preparations · 33 employees
About HCW Biologics
HCWB stock →HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and diseases in the United States. Its lead products include HCW11-018b, a novel, tetra-valent T-Cell engager; HCW11-040, a multifunctional fusion molecule that is a combination of cytokines and pembrolizumab; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which is in clinical trial in patients with alopecia areata diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 35 employees
APVO vs HCWB FAQ
Which is bigger, Aptevo Therapeutics or HCW Biologics?
HCW Biologics (HCWB) is larger, with a market capitalization of $3.58M compared with $3.24M for Aptevo Therapeutics (APVO).
Are Aptevo Therapeutics and HCW Biologics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.